Biotin-PEG4-alkyne

CAS No. 1458576-00-5

Biotin-PEG4-alkyne( —— )

Catalog No. M23621 CAS No. 1458576-00-5

Biotin-PEG4-alkyne is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 38 In Stock
25MG 67 In Stock
50MG 106 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Biotin-PEG4-alkyne
  • Note
    Research use only, not for human use.
  • Brief Description
    Biotin-PEG4-alkyne is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    Biotin-PEG4-alkyne is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PEGs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1458576-00-5
  • Formula Weight
    457.58
  • Molecular Formula
    C21H35N3O6S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (218.54 mM; Need ultrasonic)
  • SMILES
    O=C(NCCOCCOCCOCCOCC#C)CCCC[C@H]1SC[C@@]([C@@]1([H])N2)([H])NC2=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Gadd MS, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 May;13(5):514-521.
molnova catalog
related products
  • DD-03-171

    DD-03-171 is a small molecule, CGI1746-based BTK degrader (PROTAC, biochemical IC50=5.1 nM) that efficiently degrade C481S-BTK.

  • BETd-260

    BETd-260 (ZBC260, BETd260) is a novel PROTAC BET degrader that tether HJB97 to a ligand for the E3 ubiquitin ligase VHL.

  • HDAC6 degrader 9c

    HDAC6 degrader 9c (dHDAC6 9c) is a bifunctional molecule (dHDAC6) that could selectively degrade HDAC6, by conjugating non-selective HDAC inhibitor to a thalidomide-type E3 ligase ligand.